Oliver Bruhn
Kiel, SH 24105, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.
Journal: Experimental hematology & oncology
Published: July 30, 2020
Alternative Polyadenylation of ABC Transporters of the C-Family (ABCC1, ABCC2, ABCC3) and Implications on Posttranscriptional Micro-RNA Regulation.
Journal: Molecular pharmacology
Published: March 02, 2019
MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.
Journal: Oncotarget
Published: June 03, 2017
Length variants of the ABCB1 3'-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance.
Journal: Pharmacogenomics
Published: February 20, 2016
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Journal: Expert opinion on drug metabolism & toxicology
Published: August 28, 2014
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 20, 2013
Challenges in pharmacogenetics.
Journal: European journal of clinical pharmacology
Published: February 18, 2013
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
Journal: Pharmacogenetics and genomics
Published: January 14, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026